Insight journal - Deals and alliances

Current Agreements Deal Analysis Update : July 2014

Posted on 03 July 2014

Tags: , , ,

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in June 2014.

Welcome to the July 2014 edition of Current Agreements Deals Update.

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in June 2014.

Deal of the month

Acquisition agreement for Covidien for $42.9 billion

Jun 15 2014 - Medtronic, Covidien

Medtronic and Covidien have entered into a definitive agreement under which Medtronic has agreed to acquire Covidien in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion......more

Breaking news...

Co-development and licensing agreement for next-generation antibody-drug conjugates

Jun 24, 2014 - Merck KGaA, Mersana Therapeutics

Mersana Therapeutics and Merck KGaA announced an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs).....more

For more breaking deals as they are announced, visit:http://www.currentagreements.com

June 2014 has been yet another busy month with the announcement of many high value deals bringing the total number of deals for the month to 234. The top partnering deal by value was the co-development and licensing agreement for next-generation ADCs between Merck KGaA and Mersana Therapeutics worth $USD 792m. Further details can be viewed here.

On the M&A front, 33 deals were announced; the leading deal was the acquisition of Covidien by Medtronic in a deal valued at $USD 42.9bn. Further details can be viewed here.

On the financings front we recorded 119 announcements, with the leading deal by value being the senior notes financing for $4.5bn by Monsanto. Further details can be viewed here.

Our sister company, Current Partnering published several new and updated reports:

View our full list of reports here at our report store.

Our Current Partnering website showcases the leading partnering, M&A and financing deals by value.

To see all of 2014 leading deals and view the full set of Scorecards for 2014, visit  Partnering scorecard  | M&A scorecard | Financing scorecard - check them out.

We welcome your comments and feedback on this newsletter. We are also interested in hearing from any company with a deal not announced by press release; this allows us to add non-publicized deals to the database.

Best regards,

Shamini Thiagarajan

Top ten deal analysis of the month by deal value

The following are the top 10 partnering deals and alliances by value, as announced in June 2014.

 

1. Co development and licensing agreement for next-generation antibody-drug conjugates - Merck KGaA, Mersana Therapeutics - $792m

2. Asset purchase agreement for customer relationship management businesses- Cegedim, IMS Health- $573m

3. Research and licensing agreement for BNC375-  Bionomics, Merck and Co- $20m

4. Collaboration and licensing agreement for NY-ESO-1- Adaptimmune, GlaxoSmithKline - $350m

5. Settlement agreement for off-label use of Neurontin - Pfizer - $325m

6. Collaboration agreement for treatment using gene therapy - Bayer, Dimension Therapeutics - $252m

7. Co development and marketing agreement for CAR-T therapies - Cellectis, Pfizer - $185m

8. Collaboration agreement for distribution services- Medline Industries, Surgical Care Affiliates (SCA) - $175m

9. Licensing agreement for SNG001 - AstraZeneca, Synairgen- $132.25m

10. Joint venture and equity purchase agreement for speciality distribution - AmerisourceBergen, Profarma - $110m

Full details of each deal available at Current Agreements*
*Subscription required

Big pharma deal analysis June 2014

June saw 40 partnering deals announced with big pharma being at least one of the parties of the deal.

AstraZeneca were particularly active, leading partnering activities in June.

AstraZeneca partnering- May 2014

  • Collaboration agreement for dementia project -with Cardiff University, GlaxoSmithKline, Imperial College London, Johnson & Johnson, Medical Research Council, UK Biobank, UK Dementias Research Platform, University of Cambridge, University of Oxford
  • Collaboration agreement for multi-resistant bacterial diagnostic test - with Cepheid, Cubist Pharmaceuticals, GlaxoSmithKline
  • Collaboration agreement for facilitating efforts for novel drug discovery - with Academic Drug Discovery Consortium
  • Collaboration agreement for COPD managament -with Exco InTouch
  • Collaboration agreement for lung cancer master protocol trial - with Amgen, Bonnie J. Addario Lung Cancer Foundation, Foundation Medicine, Genentech, MedImmune, National Cancer Institute, Pfizer
  • Licensing agreement for SNG001 - with Synairgen
  • Collaboration agreement for diagnosis and prognosis of cancer patients - with Cancer Genetics

AstraZeneca partnering interests

AstraZeneca profile

AstraZeneca partnering report

Further details of all big pharma deals are available atCurrent Agreements.

Big biotech deal analysis June 2014

June saw 16 partnering deals announced with big biotech being at least one of the parties of the deal.

Roche were particularly active, leading partnering activity in June.

Roche partnering- June 2014

  • Collaborative R&D agreement for DNA Xpandomers -with Stratos Genomics
  • Collaboration agreement for diagnostic testing for infertility - with Ferring Pharmaceuticals
  • Joint venture agreement for multiple sclerosis -with Inception 5, Inception Sciences, Stanford University, Versant Ventures
  • Collaborative R&D agreement for novel nanomedicines using Accurins - with BIND Therapeutics
  • Grant award agreement for $0.663 for new graduates - with ARCS Foundation

Roche partnering interests

Roche profile

Roche partnering report

Further details of all big pharma deals are available at Current Agreements.

Further details of all big pharma deals are available at Current Agreements.

Current Agreements products

CP Knowledge Centre : Access the best of Current Partnering and Current Agreements with a CP Knowledge Center subscription. Buy now

 

Print Friendly, PDF & Email

Leave a Reply

 

cabannerad300x150new4gif
rauconbadgejpg
e80banner300x150animgif
cabannerad300x150new4gif
e80banner300x150animgif
a1banner300x150animgif